Page 1 of 1INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.1. Company Name and Address4. EPA ProductRegistrationOMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460DATA CALL-IN RESPONSE3. Date and Type of DCI and NumberPRODUCT SPECIFIC23-Feb-2010ID # PDCI-100801-292282. Case # and Name3028 Bioban P-1487 (*)Chemical # and Name1008014-(2-Nitrobutyl)morpholine5. I wish tocancel thisproduct registration voluntarily6. Generic Data7. Product Specific Data7a. My product is an MUP andI agree to satisfy the MUPrequirements on the attachedform entitled "RequirementsStatus and Registrant'sResponse."7b. My product is an EUP andI agree to satisfy the EUPrequirements on the attachedform entitled "RequirementsStatus and Registrant'sResponse."6a. I am claiming a GenericData Exemption because Iobtain the active ingredientfrom the source EPA registration number listed below.6b. I agree to satisfy GenericData requirements as indicatedon the attached form entitled"Requirements Status andRegistrant's Response."N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.10. Name of Company11. Phone Number9. Date8. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. I acknowledge that anyknowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law.Signature and Title of Company's Authorized Representative__________________________________INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 1 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC23-Feb-2010PDCI-100801-292282. Case # and Name3028 Bioban P-1487 (*)EPA Reg. No. 464-6748. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321Product Chemistry Data Requirements (Antimicrobial)830.15508EPX, ZProduct Identity and composition(4)830.16008EPX, ZDescription of materials used to produce the product(5)830.16208EPX, ZDescription of production process(6)830.16508EPX, ZDescription of formulation process(7)830.16708EP & possibly TGAIX, ZDiscussion of formation of impurities(8 ,9 ,10)830.17008EP & possibly TGAIX, ZPreliminary analysis(11)830.17508EPX, ZCertified limits(12)830.18008EPX, ZEnforcement analytical method(13)830.63028TGAIX, ZColor(14)830.63038TGAI & EPX, ZPhysical state(15)830.63048TGAIX, ZOdor12. Name of Company13. Phone NumberSignature and Title of Company's Authorized Representative__________________________________10. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. Iacknowledge that anyknowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law11. DateINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 2 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC23-Feb-2010PDCI-100801-292282. Case # and Name3028 Bioban P-1487 (*)EPA Reg. No. 464-6748. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321(16 ,17 ,18)830.63138TGAIX, ZStability to sunlight, normal and elevatedtemperatures, metals, and metal ions(19)830.63148EPX, ZOxidizing or reducing action(20)830.63158EPX, ZFlammability(21)830.63168EPX, ZExplodability(22)830.631716EPX, ZStorage stability of product(23)830.63198EPX, ZMiscibility(24)830.632016EPX, ZCorrosion characteristics(25)830.63218EPX, ZDielectric breakdown voltage(26 ,27)830.70008TGAI & EPX, ZpH of water solutions or suspensions830.70508TGAIX, ZUV/Visible absorption(28)830.71008EPX, ZViscosity(29 ,30)830.72008TGAI or PAIX, ZMelting point/melting rangeInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 3 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC23-Feb-2010PDCI-100801-292282. Case # and Name3028 Bioban P-1487 (*)EPA Reg. No. 464-6748. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321(31 ,32)830.72208TGAI or PAIX, ZBoiling point/boiling range(33 ,34)830.73008TGAI & EPX, ZDensity/relative density(35 ,36)830.73708TGAI or PAIX, ZDissociation constant in water(37)830.75508TGAI or PAIX, ZPartition coefficient (n-octanol/water), shake flaskmethod(38)830.75708TGAI or PAIX, ZPartition coefficient (n-octanol/water), estimation byliquid chromatography(39)830.78408TGAI or PAIX, ZWater solubility: Column elution method, shake flaskmethod(40)830.78608TGAI or PAIX, ZWater solubility, generator column method(41 ,42)830.79508TGAI or PAIX, ZVapor pressureToxicology Data Requirements (Antimicrobial)(43 ,44 ,45)870.11008EP; MP; TGAIX, ZAcute Oral Toxicity (do not select)(46 ,47 ,48,49)870.12008EP; MP; TGAIX, ZAcute dermal toxicity(50 ,51 ,52,53)870.13008EP; MP; TGAIX, ZAcute inhalation toxicityInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 4 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC23-Feb-2010PDCI-100801-292282. Case # and Name3028 Bioban P-1487 (*)EPA Reg. No. 464-6748. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321(54 ,55 ,56,57)870.25008EP; MP; TGAIX, ZAcute dermal irritation(2 ,3)870.26008EP; MP; TGAIX, ZSkin sensitization(1)870.24008EP; MP; TGAIX, ZAcute eye irritationInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateCase # and Name:3028 Bioban P-1487 (*)DCI Number:PDCI-100801-29228Page 1 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP & possibly TGAI = End- Use Product andpossibly Technical Grade Active IngredientUse Categories Key:X -Z -Materials preservativesIndustrial processes and waters1Not required if test material is corrosive to skin or has a pH of less than 2 or greater than 11.5.2For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.3Required if repeated dermal exposure is likely to occur under conditions of use.4Data must be provided in accordance with 40 CFR Part 158.325.5Data must be provided in accordance with 40 CFR Part 158.330.6Data must be provided in accordance with 40 CFR Part 158.335.7Data must be provided in accordance with 40 CFR Part 158.340.8If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).9Required for TGAIs and products produced by an integrated system.10Data must be provided in accordance with 40 CFR Part 158.345.11Data must be provided in accordance with 40 CFR Part 158.350.12Data must be provided in accordance with 40 CFR Part 158.355.13If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).14If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).15If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).Case # and Name:3028 Bioban P-1487 (*)DCI Number:PDCI-100801-29228Page 2 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP & possibly TGAI = End- Use Product andpossibly Technical Grade Active Ingredient16Data on the stability to metals and metal ions is required only if the active ingredient is expected to come in contact with either material during storage.17If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).18Data on stability of the MP and TGAI to storage at normal temperatures are required. Data on the stability of the TGAI to hightemperatures are required if the TGAI is expected to be subjectedto temperatures >50 degrees Celsius (122 degrees Fahrenheit) during production or storage.19Required if the product contains an oxidizing or reducing agent20Required when the product contains combustible liquids.21Required when the product is potentially explosive.22The 16-month deadline for submission of this study applies if you are conducting a new study for submission to the Agency to satisfy this requirement. In such case, you are required to submit aprogress report to the Agency within 3 months following the deadline for submission of the 90-Day response required for thisPDCI. Further information concerning the development of dataappears on page 7 of the Generic and Product Specific Data Call-In Notice. If you intend to submit an existing study that hasnot been submitted previously to the Agency or to cite previouslysubmitted data, the existing study or citation to the previously submitted study must be submitted along with your 90-Day Response to this PDCI. If the Agency determines that such existingdata are not adequate, you will need to develop and submit new data within the stated deadline.23Required if the product is an emulsifiable liquid and is to be diluted with petroleum solvents.24The 16-month deadline for submission of this study applies if you are conducting a new study for submission to the Agency to satisfy this requirement. In such case, you are required to submit aprogress report to the Agency within 3 months following the deadline for submission of the 90-Day response required for this PDCI. Further information concerning the development of dataappears on page 7 of the Generic and Product Specific Data Call-In Notice. If you intend to submit an existing study that hasnot been submitted previously to the Agency or to cite previouslysubmitted data, the existing study or citation to the previously submitted study must be submitted along with your 90-Day Response to this PDCI. If the Agency determines that such existingdata are not adequate, you will need to develop and submit new data within the stated deadline.25Required if the end-use product is a liquid and is to be used around electrical equipment.26Required if the product is dispersible with water.27If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).28Required if the product is a liquid.Case # and Name:3028 Bioban P-1487 (*)DCI Number:PDCI-100801-29228Page 3 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP & possibly TGAI = End- Use Product andpossibly Technical Grade Active Ingredient29Required when the TGAI is solid at room temperature.30If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).31Required if the TGAI is liquid at room temperature.32If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).33True density or specific density are required for all test substances. Data on bulk density is required for MPs that are solidat room temperature.34If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).35Required when the test substance contains an acid or base functionality (organic or inorganic) or an alcoholic functionality (organic).36If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).37Required if the TGAI or PAI is organic and non-polar.38Required if the TGAI or PAI is organic and non-polar.39If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).40If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).41Not required for salts.42If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).43For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.Case # and Name:3028 Bioban P-1487 (*)DCI Number:PDCI-100801-29228Page 4 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP & possibly TGAI = End- Use Product andpossibly Technical Grade Active Ingredient44Not required if test material is a gas or highly volatile.45Diluted EP testing is required to support the end product registration if results using the EP meet the criteria for restricted use classification under 40 CFR Part 152.170(b) or special reviewconsideration under 40 CFR Part 154.7(a)(1).46Not required if test material is corrosive to skin or has pH < 2 or >11.5; such a product will be classified as Toxicity Category I on the basis of potential dermal toxicity.47For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.48Not required if test material is a gas or highly volatile.49Diluted EP testing is required to support the end product registration if results using the EP meet the criteria for restricted use classification under 40 CFR Part 152.170(b) or special reviewconsideration under 40 CFR Part 154.7(a)(1).50Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g. gas, volatile substances, or aerosol particulate).51The 870 series studies for the MP and EP are intended to provide data on the acute toxicity of the product. Waivers for any orall of these studies may be granted when the applicant candemonstrate that the combination of inert ingredients is not likely to pose any significant human health risks. Where appropriate, the limit dose approach to testing is recommended.52Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g., gas, vapor, aerosol or particulates).53For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.54Not required if test material is corrosive to skin or has pH < 2 or > 11.5; such a product will be classified as Toxicity Category I on the basis of potential eye irritation effects.55For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.56Not required if test material is a gas or highly volatile.57Required if intended use of the antimicrobial pesticide product will involve purposeful application on human skin or will result in comparable exposure to the product (e.g. uses in swimming poolwater), or if the active ingredient of the product is known or expected to be metabolized differently by the dermal route of exposure than by the oral route, and a metabolite of the active ingredientis the toxic moiety. The EP shall also be tested if any component of the EP may increase dermal absorption of the active ingredient(s) or potentiate toxic or pharmacologic effects.United States Environmental ProtectionAgency Washington, D.C. 20460LIST OF ALL REGISTRANTS SENT THIS DATA CALL-IN NOTICECo. Nr.Company NameAgent ForAddressCity & StateZipCase # and Name:3028,Bioban P-1487 (*)DOW CHEMICAL CO., THETHE DOW CHEMICAL COMPANY1500 EAST LAKE COOK ROADBUFFALO GROVEIL60089464KOP-COAT, INC436 SEVENTH AVENUEPITTSBURGHPA1521960061